Minerva Neurosciences reports $2.7 mln Q3 net loss

Minerva Neurosciences

05/11/2025 12:39

Overview

Minerva reports Q3 net loss of $2.7 mln, contrasting with net income in Q3 2024

Company's Q3 operating expenses decreased due to lower R&D and G&A costs

Minerva secures $80 mln in financing for Phase 3 trial of roluperidone

Outlook

Minerva anticipates increased R&D and administrative expenses for Phase 3 trial and NDA resubmission

Company expects to have sufficient funds for Phase 3 study and potential US launch

Result Drivers

FINANCING - Minerva received $80 mln in private placement to fund Phase 3 trial of roluperidone

LOWER R&D EXPENSES - R&D expenses decreased due to lower costs for drug substance validation and consultant fees

LOWER G&A EXPENSES - G&A expenses fell due to reduced professional service fees and insurance costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.36
Q3 Net Income
-$2.74 mln
Q3 Income from Operations
-$2.84 mln
Q3 Operating Expenses
$2.84 mln


Press Release: ID:nGNXbBfpzw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)